Drug intelligence / Profile preview

GLO1 shRNA

Development stage: Unknown
Modality: Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
Administration: Transfection Into Cells

Overview

GLO1 shRNA is a type of short hairpin RNA (shRNA) designed to silence the expression of **Glyoxalase 1 (GLO1)**, a key enzyme in the detoxification of methylglyoxal (MG), a compound involved in diabetic complications. shRNA works by being processed into small interfering RNA (siRNA) that specifically targets and degrades GLO1 mRNA, leading to reduced GLO1 protein levels and increased accumulation of MG. This can affect cellular processes such as glucose uptake and insulin signaling, as seen in studies where GLO1 knockdown enhances GLUT4 translocation and glucose uptake in cells[1][2][4].

Targets

GLO1 (Glyoxalase 1)

Beyond the preview

Go deeper on GLO1 shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLO1 shRNA.

Explore the full profile